Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Dexcom (DXCM) Cost of Revenue (2016 - 2025)

Dexcom (DXCM) has disclosed Cost of Revenue for 16 consecutive years, with $466.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 2.01% to $466.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 16.64% increase, with the full-year FY2025 number at $1.9 billion, up 16.64% from a year prior.
  • Cost of Revenue was $466.9 million for Q4 2025 at Dexcom, down from $477.9 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $477.9 million in Q3 2025 to a low of $161.1 million in Q1 2021.
  • A 5-year average of $329.2 million and a median of $338.3 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 43.2% in 2022, then grew 2.01% in 2025.
  • Dexcom's Cost of Revenue stood at $225.6 million in 2021, then grew by 21.41% to $273.9 million in 2022, then skyrocketed by 37.97% to $377.9 million in 2023, then increased by 21.12% to $457.7 million in 2024, then increased by 2.01% to $466.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Cost of Revenue are $466.9 million (Q4 2025), $477.9 million (Q3 2025), and $468.3 million (Q2 2025).